<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02407210</url>
  </required_header>
  <id_info>
    <org_study_id>HR-AQST-2014</org_study_id>
    <nct_id>NCT02407210</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension</brief_title>
  <official_title>A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of azilsartan compared to olmesartan medoxomil in
      patients with grade I or II essential hypertension
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough sitting diastolic blood pressure (change from end of the run-in period to end of the treatment period)</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough sitting systolic blood pressure (change from end of the run-in period to end of the treatment period)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough sitting diastolic and systolic blood pressure (change from end of the run-in period to Week 8 of the treatment period)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough sitting diastolic and systolic blood pressures at each evaluation</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>responder rate; rate of patients with normalized blood pressure</measure>
    <time_frame>8 weeks and 16 weeks</time_frame>
    <description>Responder is defined as a ≥20mmHg decrease in sitting trough SBP and a ≥10mmHg decrease in sitting trough DBP，or a sitting trough SBP of ＜140mmHg and a sitting trough DBP of ＜90mmHg；normalized blood pressure is defined as a sitting trough SBP of ＜140mmHg and a sitting trough DBP of ＜90mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation by ABPM (1: 24-hour mean change in diastolic and systolic blood pressures, 2: Trough/Peak ratio of diastolic and systolic blood pressures)(change from end of the run-in period to Week 14 of the treatment period)</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>azilsartan group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once-daily oral administration of 20 or 40 mg tablet before or after breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olmesartan medoxomil group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once-daily oral administration of 20 or 40 mg tablet before or after breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azilsartan</intervention_name>
    <arm_group_label>azilsartan group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil</intervention_name>
    <arm_group_label>olmesartan medoxomil group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Both sexes. eighteen years or older and no more than 70 years at the time of informed
             consent

          2. Grade I or II essential hypertension

          3. Both sitting systolic and diastolic blood pressures at Week 0 during the run-in period
             meet the following criteria:

             Sitting systolic blood pressure: greater than or equal to 150 mmHg and less than 180
             mmHg

             Sitting diastolic blood pressure: greater than or equal to 95 mmHg and less than 110
             mmHg

          4. Able to understand the content of the study and comply with the study and to give
             informed consent in writing before participating in the study

        Exclusion Criteria:

          1. Secondary hypertension, grade III hypertension (sitting systolic blood pressure
             greater than or equal to 180 mmHg or sitting diastolic blood pressure greater than or
             equal to 110 mmHg), or malignant hypertension，hypertensive emergencies，hypertensive
             urgencies

          2. The following circulatory-related diseases or symptoms:

        (1) Cardiac disease: angina pectoris; valvular stenosis; atrial fibrillation; the following
        diseases requiring medication: congestive heart failure or arrhythmia； (2) Cerebrovascular
        disorder: cerebral infarction, cerebral hemorrhage (onset within 24 weeks before start of
        the screening period), transient ischemic attack (onset of an attack within 24 weeks before
        start of the screening period)； (3) Vascular disease: arteriosclerosis obliterans with
        symptoms of intermittent claudication； (4) Progressive hypertensive retinopathy:
        hemorrhage, exudation, or papilledema (observed within 24 weeks after start of the
        screening period)

        3. Decrease in sitting diastolic blood pressure by 8 mmHg or more at the end of the run-in
        period (Week 0) compared to the start of the screening period

        4. Day/night reversal, e.g., nightshift worker

        5. Unilateral or bilateral renal artery stenosis

        6. Clinically apparent hepatic and renal impairment (e.g., with AST and ALT values of 2.5 x
        upper limit of normal or higher, with serum creatinine value of 1.5 x upper limit of normal
        or higher during the screening period)

        7. Hyperkalemia (with a laboratory value of 5.5 mEq/L or higher during the run-in period)

        8. Malignant tumor

        9. Compliance with the study drug of less than 80% during the run-in period

        10. Poorly-controlled diabetes mellitus (fasting plasma glucose greater than
        11mmol/L)，and/or complications (kidney disease, peripheral neuropathy) at Screening.

        11. History of hypersensitivity or allergy to olmesartan medoxomil tablets and related
        drugs (ARB, ACE inhibitors, and renin inhibitors)

        12. History of drug abuse (defined as illegal drug use) or alcohol dependency within 2
        years before start of the screening period

        13. Requirement of the excluded treatment

        14. Pregnant or lactating women

        15. Participation in another clinical trial or post-marketing clinical trial within 30 days
        before start of the screening period

        16. Dangerous machinery operator such as aerial worker，motor vehicle driver
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing ANZHEN Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changsheng Ma, Professor</last_name>
      <phone>86-010-64456078</phone>
      <email>chshma@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Changsheng Ma, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Azilsartan，Olmesartan Medoxomil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

